lexicographer
发表于 2025-3-21 19:19:15
书目名称Drug Resistance in Leukemia and Lymphoma III影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0283123<br><br> <br><br>书目名称Drug Resistance in Leukemia and Lymphoma III读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0283123<br><br> <br><br>
思考
发表于 2025-3-21 22:06:00
https://doi.org/10.1007/978-3-7091-9414-0 strategies are being developed to circumvent drug resistance by inhibiting P-gp, prospective studies concerning the clinical relevance of P-gp in childhood leukemia are warranted. . P-gp was studied in 102 consecutive cases of de novo childhood ALL and in 34 relapsed patients. An immunocytochemical
Astigmatism
发表于 2025-3-22 04:08:28
http://reply.papertrans.cn/29/2832/283123/283123_3.png
emulsify
发表于 2025-3-22 08:16:31
https://doi.org/10.1007/978-3-642-83312-0Cyclosporin A (CsA), PSC833 and GF120918. We describe an investigation into the expression, using MRK16 and UIC2, and function of P-gp using daunorubicin with and without modulators by flow cytometric analysis on previously frozen blast cells from 27 patients with primary or secondary AML. We compar
障碍物
发表于 2025-3-22 11:57:54
http://reply.papertrans.cn/29/2832/283123/283123_5.png
geriatrician
发表于 2025-3-22 15:39:35
http://reply.papertrans.cn/29/2832/283123/283123_6.png
geriatrician
发表于 2025-3-22 20:19:06
http://reply.papertrans.cn/29/2832/283123/283123_7.png
解决
发表于 2025-3-22 21:14:08
http://reply.papertrans.cn/29/2832/283123/283123_8.png
endure
发表于 2025-3-23 04:34:05
Väter, Männer und kindliche Entwicklungcellular mechanisms underlying this increased expression are completely unknown. Point mutations in the .1 promoter have been found in osteogenic sarcoma (Stein et al., Eur J of Cancer, 30A: 1541–1545, 1994). We therefore analyzed DNA from hematological malignancies for .1 promoter point mutations.
正面
发表于 2025-3-23 06:15:30
https://doi.org/10.1007/978-3-322-85040-9ty can also be increased by combining the results of more than one assay. We have used a combination of flow cytometric assays to define MDR positive and negative blasts in 47 AML patients entered into MRC trials. Our primary test is a standardised and reproducible assay for anthracycline accumulati